301075.SZ · 多瑞医药
China A-shares · RS rating 68 · As of 2026-10-14
| Price | 56.34 CNY |
|---|---|
| 1-day change | -3.5% |
| RS rating (overall / 1M / 3M / 12M) | 68 / 40 / 43 / 89 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 34 / 33 / 10 |
| Industry group (rank) | Medical-Generic Drugs (40) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +95.0% |
| Distance from 52-week high | +40.3% |
| Market cap (USD) | $717.2M |